New research suggests GLP-1 weight-loss drugs may affect cancer risk and outcomes, but researchers say more clinical trials are needed.
Weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are attracting attention for another reason beyond their ability to help people lose weight.
Researchers are increasingly investigating whether these medications could also influence the development and progression of certain cancers.
The emerging evidence is intriguing, but scientists are urging caution. Most of the research so far is observational, meaning it can identify an association between GLP-1 medications and cancer outcomes without proving that the drugs themselves caused the difference.
Why Scientists Are Studying GLP-1 Drugs and Cancer
GLP-1 receptor agonists were initially developed to treat conditions such as Type 2 diabetes before becoming widely used for weight management.
The drugs include semaglutide-based medications such as Ozempic and Wegovy, along with tirzepatide drugs such as Mounjaro and Zepbound.
Their potential connection to cancer is attracting interest partly because excess body weight is an established risk factor for numerous cancers.
Researchers are now asking whether reducing obesity and improving metabolic health could also change a person’s cancer risk.
Obesity Is Already Linked to Cancer
Obesity can influence the body through several biological pathways, including chronic inflammation, insulin resistance and hormonal changes.
Those processes have been associated with the development or progression of several cancers.
That has created a logical research question: if a medication substantially reduces body weight and improves metabolic health, could some of the cancer risks associated with obesity also decline?
Researchers say the answer remains uncertain, but the evidence is becoming difficult to ignore.
Studies Point to Potentially Lower Cancer Risk
A large observational study involving more than 110,000 women between ages 45 and 80 found that GLP-1 users were about 30% less likely to develop breast cancer than women who did not take the medications.
The research was presented at the 2026 American Society of Clinical Oncology annual meeting.
Researchers emphasized that the study was observational and therefore cannot establish that GLP-1 medications prevent breast cancer.
Other recent studies have also examined whether GLP-1 use may be associated with better outcomes among people who already have cancer.
Researchers See Signals Beyond Breast Cancer
A broader 2026 systematic review and meta-analysis examined 78 observational studies and found statistically significant associations between GLP-1 use and lower risks for several obesity-associated cancers.
The analysis reported lower risks for cancers including colorectal, endometrial, esophageal, gallbladder, liver, ovarian, pancreatic and stomach cancers, among others.
However, the researchers analyzed observational evidence rather than randomized clinical trials, which limits conclusions about cause and effect.
Could Weight Loss Be the Main Explanation?
One of the biggest unanswered questions is whether the potential cancer benefits come directly from GLP-1 medications or indirectly from the weight loss and metabolic improvements they produce.
People taking these drugs can experience substantial reductions in body weight.
If excess weight itself contributes to cancer development or progression, reducing obesity could explain at least part of the association seen in observational studies.
Researchers are also investigating other possible mechanisms, including effects on inflammation, insulin sensitivity and biological pathways involved in tumor growth.
The Drug May Have Effects Beyond Weight Loss
Scientists are particularly interested in whether GLP-1 signaling can influence biological processes independently of weight reduction.
That possibility remains under investigation.
At this point, researchers cannot determine how much of the observed association is attributable to weight loss, improved metabolic health or direct effects of the medications.
Researchers Urge Caution Over Cancer Claims
Despite the encouraging findings, experts are not recommending GLP-1 medications as cancer-prevention drugs.
The American Cancer Society notes that evidence suggesting lower risks for some cancers is growing, but additional research is needed.
The organization also points out that some animal studies have raised concerns about a rare form of thyroid cancer, known as medullary thyroid cancer. For that reason, GLP-1 medications carry specific warnings and are not recommended for people with certain personal or family medical histories.
Clinical Trials Are the Missing Piece
Randomized clinical trials are considered the strongest way to determine whether a treatment actually changes cancer outcomes.
Those trials have not yet established that GLP-1 drugs prevent cancer or improve cancer survival.
Until that evidence is available, researchers say the current findings should be viewed as an important signal for further investigation rather than proof that weight-loss medications can treat or prevent cancer.
What This Could Mean for the Future
The growing body of research is changing how scientists think about GLP-1 medications.
What began primarily as a treatment for diabetes and obesity is now being studied for potential effects across several areas of health, including cardiovascular disease and cancer.
The possibility of a connection between weight-loss drugs and cancer outcomes is particularly significant because obesity itself is a major cancer risk factor.
But researchers still have to answer a crucial question: are GLP-1 drugs directly changing cancer biology, or are the benefits largely a consequence of losing weight and improving metabolic health?
Future clinical trials will be needed to separate those possibilities.
For now, the evidence provides a promising research direction, but GLP-1 medications should not be viewed as established cancer treatments or prevention drugs.
Also read: Trump Revives Supreme Court Immigration Fight
